Boothbay Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-58,600
| Closed | -$1.69M | – | 1480 |
|
|
2024
Q3 | $1.69M | Buy |
+58,600
| New | +$2.17M | 0.04% | 579 |
|
|
2024
Q2 | – | Sell |
-81,700
| Closed | -$4.8M | – | 1504 |
|
|
2024
Q1 | $4.8M | Buy |
+81,700
| New | +$5.21M | 0.09% | 238 |
|
|
2023
Q4 | – | Sell |
-8,300
| Closed | -$316K | – | 1637 |
|
|
2023
Q3 | $316K | Sell |
8,300
-170,300
| -95% | -$7.48M | 0.01% | 1227 |
|
|
2023
Q2 | $16.3M | Buy |
+178,600
| New | +$15.4M | 0.36% | 34 |
|
|
2023
Q1 | – | Sell |
-30,800
| Closed | -$1.59M | – | 2110 |
|
|
2022
Q4 | $1.59M | Sell |
30,800
-66,500
| -68% | -$3.53M | 0.04% | 692 |
|
|
2022
Q3 | $6.65M | Buy |
97,300
+66,500
| +216% | +$3.94M | 0.17% | 111 |
|
|
2022
Q2 | $1.39M | Hold |
30,800
| – | – | 0.04% | 685 |
|
|
2022
Q1 | $1.56M | Buy |
+30,800
| New | +$1.36M | 0.04% | 687 |
|
|
2021
Q4 | – | Sell |
-35,500
| Closed | -$1.17M | – | 1843 |
|
|
2021
Q3 | $1.17M | Buy |
35,500
+1,400
| +4% | +$78.7K | 0.03% | 685 |
|
|
2021
Q2 | $2.15M | Buy |
+34,100
| New | +$1.76M | 0.07% | 356 |
|
|
2020
Q2 | – | Sell |
-118
| Closed | -$316K | – | 953 |
|
|
2020
Q1 | $316K | Sell |
118
-376
| -76% | -$13.3K | 0.03% | 559 |
|
|
2019
Q4 | $1.51M | Buy |
+494
| New | +$13.7K | 0.13% | 215 |
|
Other funds holding APLS
Boothbay Fund Management's APLS Position: Q2 2026 in Review
Boothbay Fund Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 183,522 shares — an estimated $7.38M sold.
Boothbay Fund Management first reported a position in APLS in Q4 2018 and held it in 14 quarters. The position peaked at $7.38M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Boothbay Fund Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Boothbay Fund Management sold 183,522 Apellis Pharmaceuticals shares in Q2 2026, an estimated $7.38M.
- Boothbay Fund Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 14 quarters.
- Boothbay Fund Management's Apellis Pharmaceuticals position peaked at $7.38M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.